BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20804567)

  • 1. The Met oncogene and basal-like breast cancer: another culprit to watch out for?
    Gastaldi S; Comoglio PM; Trusolino L
    Breast Cancer Res; 2010; 12(4):208. PubMed ID: 20804567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.
    Gastaldi S; Sassi F; Accornero P; Torti D; Galimi F; Migliardi G; Molyneux G; Perera T; Comoglio PM; Boccaccio C; Smalley MJ; Bertotti A; Trusolino L
    Oncogene; 2013 Mar; 32(11):1428-40. PubMed ID: 22562252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teamwork: The tumor cell edition.
    Cleary AS
    Science; 2015 Dec; 350(6265):1174-5. PubMed ID: 26785463
    [No Abstract]   [Full Text] [Related]  

  • 5. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
    Graveel CR; DeGroot JD; Su Y; Koeman J; Dykema K; Leung S; Snider J; Davies SR; Swiatek PJ; Cottingham S; Watson MA; Ellis MJ; Sigler RE; Furge KA; Vande Woude GF
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12909-14. PubMed ID: 19567831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.
    Ponzo MG; Lesurf R; Petkiewicz S; O'Malley FP; Pinnaduwage D; Andrulis IL; Bull SB; Chughtai N; Zuo D; Souleimanova M; Germain D; Omeroglu A; Cardiff RD; Hallett M; Park M
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12903-8. PubMed ID: 19617568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
    Pires MM; Hopkins BD; Saal LH; Parsons RE
    Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
    Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
    Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Wnt/β-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome.
    Holland JD; Györffy B; Vogel R; Eckert K; Valenti G; Fang L; Lohneis P; Elezkurtaj S; Ziebold U; Birchmeier W
    Cell Rep; 2013 Dec; 5(5):1214-27. PubMed ID: 24290754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and functional significance of c-Met in breast cancer: a review.
    Ho-Yen CM; Jones JL; Kermorgant S
    Breast Cancer Res; 2015 Apr; 17(1):52. PubMed ID: 25887320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
    Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
    Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
    Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
    Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear CSPP1 expression defined subtypes of basal-like breast cancer.
    Sternemalm J; Russnes HG; Zhao X; Risberg B; Nord S; Caldas C; Børresen-Dale AL; Stokke T; Patzke S
    Br J Cancer; 2014 Jul; 111(2):326-38. PubMed ID: 24901235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATF3-Induced Mammary Tumors Exhibit Molecular Features of Human Basal-Like Breast Cancer.
    Yan L; Gaddis S; Coletta LD; Repass J; Powell KL; Simper MS; Chen Y; Byrom M; Zhong Y; Lin K; Liu B; Lu Y; Shen J; MacLeod MC
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33652981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential targeted therapy options in the management of basal cell subtype of breast carcinoma.
    Harputluoglu H; Dizdar O; Altundag K
    Hum Pathol; 2007 Dec; 38(12):1869; author reply 1870. PubMed ID: 17915288
    [No Abstract]   [Full Text] [Related]  

  • 17. Infiltrating Mast Cell-Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype.
    Majorini MT; Cancila V; Rigoni A; Botti L; Dugo M; Triulzi T; De Cecco L; Fontanella E; Jachetti E; Tagliabue E; Chiodoni C; Tripodo C; Colombo MP; Lecis D
    Cancer Res; 2020 Jun; 80(11):2311-2324. PubMed ID: 32179512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
    Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
    Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
    Li Y; Yang W; Yang Q; Zhou S
    Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
    Fadare O; Tavassoli FA
    Adv Anat Pathol; 2007 Sep; 14(5):358-73. PubMed ID: 17717437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.